Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
839 Leser
Artikel bewerten:
(2)

Novo Nordisk A/S: Novo Nordisk - major shareholder announcement

Bagsværd, Denmark, 14February 2022 - Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Further information

Media:
Martin Havtorn Petersen +45 3075 5246 m (mailto:mhpz@novonordisk.com)hpz@ (mailto:mhpz@novonordisk.com)novonordisk.com (mailto:mhpz@novonordisk.com)
Michael Bachner (US)+1 609 664 7308 mzyb@novonordisk.com (mailto:mzyb@novonordisk.com)
Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com (mailto:dabo@novonordisk.com)
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com (mailto:arnd@novonordisk.com)
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com (mailto:dhel@novonordisk.com)
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com (mailto:jrde@novonordisk.com)
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com (mailto:mjhr@novonordisk.com)

Company announcement No 12 / 2022

Annex

Name% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
BlackRock Japan Co., Ltd. Below 5%
BlackRock Investment Management, LLC Below 5%
BlackRock Investment Management (UK) Limited Below 5%
BlackRock Investment Management (Australia) Limited Below 5%
Blackrock International Limited Below 5%
BlackRock Fund Advisors Below 5%
BlackRock Financial Management, Inc. Below 5%
BlackRock Asset Management North Asia Limited Below 5%
BlackRock Asset Management Deutschland AG Below 5%
BlackRock Asset Management Canada Limited Below 5%
BlackRock Advisors, LLC Below 5%
BlackRock (Singapore) Limited Below 5%
BlackRock Asset Management Ireland Limited Below 5%
Aperio Group, LLC Below 5%

Attachment

  • PR220214_Major_shareholder_information (https://ml-eu.globenewswire.com/Resource/Download/ae15d949-5d56-4dba-9f8c-5d727cd791b3)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2022 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.